WEST LAFAYETTE, Ind., March 26, 2019 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today the appointment of Donna Haire as Executive Vice President of Regulatory and Quality. Ms. Haire will head the company's regulatory strategy and quality efforts for the company's cancer-illuminating small molecule portfolio, including OTL38.
"Ms. Haire's broad experience in the fields of radiology, drug, device and combination products within regulatory, quality and clinical affairs provides an excellent fit for On Target Laboratories as we advance our clinical programs and expand our platform," said Martin Low, CEO of On Target Laboratories. "She has arrived at a critical time for the company as we continue to pioneer in cancer visualization probes and accomplish our clinical goals."
Prior to this position, she was the Vice President, Head of Medical Care Global Regulatory Affairs at Bayer and an AdvaMed Board Committee Member and Board of Directors Authorized Representative. Ms. Haire has also served as the Senior Vice President of Regulatory, Quality, Clinical and Medical Affairs at AngioDynamics and has held senior level positions at Philips Healthcare, Medtronic, Avery Dennison Medical and STERIS Corporation. She has been a featured speaker at key regulatory compliance events and published numerous articles on navigating global regulatory environments. Ms. Haire was also a lead U.S. Industry representative for several international trade negotiations. She holds a M.S. in Biology from Cleveland State University.
"It is an exciting time to join On Target Laboratories as the company has several product candidates in clinical trials," said Ms. Haire. "On Target Laboratories is leading the charge to develop a safe and effective cancer visualization molecule that I believe will have significant benefits for surgeons and patients."
About On Target Laboratories, Inc.
On Target Laboratories, Inc., is in the business of discovering, developing and commercializing small molecules that, when conjugated with fluorescent dyes, target and illuminate specific cancerous cells and other diseased tissue. These conjugates can be used by doctors, including surgeons, worldwide to better diagnose and treat a wide range of diseases from cancer to inflammation-related disorders. OTL38 is currently under clinical development for use in ovarian and lung cancer surgery. For more information visit www.ontargetlaboratories.com.
Travis Kruse, Ph.D.
Russo Partners LLC
Purdue Research Foundation:
SOURCE On Target Laboratories, Inc.